泰国GPO生产10μg HXP-GPOVac新冠疫苗的安全性与免疫原性:III期随机双盲对照试验
该III期双盲随机对照试验在泰国纳入4000名已完成两剂基础免疫的健康或临床稳定成人,按3:1随机接种单剂HXP-GPOVac或VAXZEVRIA。结果显示HXP-GPOVac solicited AE发生率43.7%低于VAXZEVRIA的53.5%(p=0.01),第14天NT50 GMC比值0.83(95%CI下限0.74)、SCR差值-2.35%(95%CI下限-8.72%),均满足非劣效标准。
要点
- HXP-GPOVac接种后solicited AE发生率43.7%,低于VAXZEVRIA的53.5%(p=0.01)。
- 未报告疫苗相关严重不良事件,多数solicited AE为轻度。
- 第14天NT50 GMC比值0.83(95%CI下限0.74),SCR差值-2.35%(95%CI下限-8.72%),均达非劣效。
核心结论
- HXP-GPOVac耐受性良好,接种后14天免疫原性非劣效于VAXZEVRIA。
研究设计与样本
- III期双盲随机活性对照试验,在泰国那空拍侬府纳入4000名已完成两剂授权新冠疫苗基础免疫的健康或临床稳定成人,按3:1随机接种HXP-GPOVac或VAXZEVRIA。
主要发现
- solicited AE发生率HXP-GPOVac组43.7% vs VAXZEVRIA组53.5%(p=0.01),多数为轻度。
- 未报告疫苗相关严重不良事件。
- 第14天NT50 GMC比值(HXP-GPOVac/VAXZEVRIA)为0.83(95%CI下限0.74)。
- 第14天SCR差值为-2.35%(95%CI下限-8.72%)。
关键数值与推荐
- 非劣效预设标准:NT50 GMC比值95%CI下限>0.67,且SCR差值95%CI下限>-10%。
- 本试验两项NT50终点均满足上述非劣效标准。
临床怎么用
- 提示HXP-GPOVac可作为已完成基础免疫成人的单剂加强候选疫苗。
- 需更大规模研究评估HXP-GPOVac的临床效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HXP-GPOVac is a Thailand-produced, egg-based, inactivated recombinant Newcastle disease virus (NDV)-chimera vaccine expressing a membrane-anchored, prefusion-stabilized SARS-CoV-2 spike (NDV-HXP-S), developed to expand vaccine access. This phase III trial evaluated the safety and immunogenicity of a single HXP-GPOVac dose in healthy or clinically stable Thai adults who had completed a two-dose primary series of an authorized COVID-19 vaccine. METHODS: In this double-blind, randomized, active-controlled trial in Nakhon Phanom, Thailand, 4000 participants were randomized 3:1 to receive HXP-GPOVac or VAXZEVRIA (AstraZeneca, ChAdOx1 nCoV-19). Safety outcomes included incidence, severity, and vaccine-relatedness of adverse events (AEs). AE incidence was compared between vaccine groups using Chi-square or Fisher's exact test. Immunogenicity was assessed by pseudovirus neutralization assay for 50% neutralizing antibody titers (NT50) and ELISA for anti-Spike IgG. Non-inferiority was prespecified for NT50-based endpoints at day 14, defined by (i) a geometric mean concentration (GMC) ratio (HXP-GPOVac/VAXZEVRIA) with 95% CI lower bound >0.67 and (ii) a seroconversion rate (SCR) difference with 95% CI lower bound > -10%. RESULTS: Solicited AEs occurred in 43.7% of HXP-GPOVac recipients versus 53.5% of VAXZEVRIA recipients (p = 0.01). Most solicited AEs were mild. No vaccine-related serious AEs were reported. At day 14, the NT50 GMC ratio (HXP-GPOVac/VAXZEVRIA) was 0.83 (95% CI lower bound: 0.74), and the SCR difference was -2.35% (95% CI lower bound: -8.72%), both meeting non-inferiority criteria. CONCLUSION: HXP-GPOVac was well-tolerated and demonstrated non-inferior immunogenicity compared with VAXZEVRIA at 14 days after vaccination. These findings provide rationale for larger studies to assess HXP-GPOVac clinical efficacy.
引用
- Prasert K, Nakphook S, Kittiwatanachod J, et al. Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA. Vaccine. 2026. PMID: 42869875. doi:10.1016/j.vaccine.2026.129230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。